Cite
Hummel HD, Kufer P, Grüllich C, et al. Pasotuxizumab, a BiTE. Immunotherapy. 2020;13(2):125-141doi: 10.2217/imt-2020-0256.
Hummel, H. D., Kufer, P., Grüllich, C., Seggewiss-Bernhardt, R., Deschler-Baier, B., Chatterjee, M., Goebeler, M. E., Miller, K., de Santis, M., Loidl, W., Dittrich, C., Buck, A., Lapa, C., Thurner, A., Wittemer-Rump, S., Koca, G., Boix, O., Döcke, W. D., Finnern, R., Kusi, H., Ajavon-Hartmann, A., Stienen, S., Sayehli, C. M., Polat, B., & Bargou, R. C. (2021). Pasotuxizumab, a BiTE. Immunotherapy, 13(2), 125-141. https://doi.org/10.2217/imt-2020-0256
Hummel, Horst-Dieter, et al. "Pasotuxizumab, a BiTE." Immunotherapy vol. 13,2 (2021): 125-141. doi: https://doi.org/10.2217/imt-2020-0256
Hummel HD, Kufer P, Grüllich C, Seggewiss-Bernhardt R, Deschler-Baier B, Chatterjee M, Goebeler ME, Miller K, de Santis M, Loidl W, Dittrich C, Buck A, Lapa C, Thurner A, Wittemer-Rump S, Koca G, Boix O, Döcke WD, Finnern R, Kusi H, Ajavon-Hartmann A, Stienen S, Sayehli CM, Polat B, Bargou RC. Pasotuxizumab, a BiTE. Immunotherapy. 2021 Feb;13(2):125-141. doi: 10.2217/imt-2020-0256. Epub 2020 Nov 10. PMID: 33172323.
Copy
Download .nbib